ChartMill · Sep 17, 2026
Which stocks have an unusual volume on Thursday?
Let's have a look at the stocks with an unusual volume in today's session.
NASDAQ · SLXN
Healthcare · Biotechnology
$0.32
Down-$0.08 (-19.63%)
Updated Sep 24, 2026, 8:48 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SLXN closed at $0.32 after 20 trading sessions, down 11.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 23, 2026 | $0.3386 | $0.3824 | $0.30 | $0.3153 | 8.32M |
| Sep 22, 2026 | $0.4921 | $0.50 | $0.3282 | $0.3923 | 32.53M |
| Sep 21, 2026 | $0.42 | $0.6303 | $0.4149 | $0.5441 | 20.13M |
| Sep 18, 2026 | $0.3855 | $0.4492 | $0.384 | $0.4355 | 27.81M |
| Sep 17, 2026 | $0.366 | $0.39 | $0.3477 | $0.38 | 8.52M |
| Sep 16, 2026 | $0.34 | $0.3495 | $0.3222 | $0.34 | 2.48M |
| Sep 15, 2026 | $0.335 | $0.3546 | $0.3241 | $0.34 | 36.97M |
| Sep 14, 2026 | $0.3479 | $0.40 | $0.344 | $0.3854 | 890.63K |
| Sep 11, 2026 | $0.36 | $0.3878 | $0.3393 | $0.3573 | 2.58M |
| Sep 10, 2026 | $0.4152 | $0.4871 | $0.3849 | $0.4225 | 118.95M |
| Sep 9, 2026 | $0.3452 | $0.3557 | $0.335 | $0.3495 | 67.4K |
| Sep 8, 2026 | $0.364 | $0.364 | $0.3353 | $0.3449 | 189.02K |
| Sep 4, 2026 | $0.372 | $0.38 | $0.3516 | $0.3518 | 204.05K |
| Sep 3, 2026 | $0.36 | $0.3743 | $0.3515 | $0.3516 | 130.98K |
| Sep 2, 2026 | $0.38 | $0.3899 | $0.3502 | $0.3512 | 184.1K |
| Sep 1, 2026 | $0.36 | $0.39 | $0.36 | $0.3701 | 179.94K |
| Aug 31, 2026 | $0.369 | $0.3755 | $0.36 | $0.3697 | 155.69K |
| Aug 28, 2026 | $0.37 | $0.3759 | $0.353 | $0.3628 | 77.19K |
| Aug 27, 2026 | $0.3504 | $0.38 | $0.3501 | $0.3602 | 286.23K |
| Aug 26, 2026 | $0.374 | $0.374 | $0.3506 | $0.3549 | 228.41K |
The latest Smart Investors Daily articles mentioning SLXN.
SLXN research
Company profile and research snapshot.
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 15, 2025 | Litchfield Hills | Buy | — |
| Mar 20, 2025 | Maxim Group | Buy | — |
| Nov 1, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
ChartMill · Sep 17, 2026
Let's have a look at the stocks with an unusual volume in today's session.
ChartMill · Sep 15, 2026
Let's have a look at the stocks with an unusual volume in today's session.
Benzinga · Sep 11, 2026
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 110.6% to $1.39 during Friday's regular session. Tenon Medical (NASDAQ:TNON) shares rose 69.71% to $8.99. The company's market cap stands at
ChartMill · Sep 10, 2026
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning SLXN.